vs
Esperion Therapeutics, Inc.（ESPR）与LendingClub Corp（LC）财务数据对比。点击上方公司名可切换其他公司
LendingClub Corp的季度营收约是Esperion Therapeutics, Inc.的1.5倍（$252.3M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 15.9%），过去两年LendingClub Corp的营收复合增速更高（16.1% vs 10.6%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
LendingClub Corp是总部位于美国加利福尼亚州旧金山的金融服务企业，是全球首家将旗下产品作为证券完成注册的P2P借贷平台，同时支持贷款在二级市场交易。巅峰时期它是全球规模最大的P2P借贷平台，截至2015年12月31日，平台累计促成贷款发放额达159.8亿美元。
ESPR vs LC — 直观对比
营收规模更大
LC
是对方的1.5倍
$168.4M
营收增速更快
ESPR
高出127.8%
15.9%
两年增速更快
LC
近两年复合增速
10.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $252.3M |
| 净利润 | — | $51.6M |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | — |
| 净利率 | — | 20.5% |
| 营收同比 | 143.7% | 15.9% |
| 净利润同比 | — | 341.0% |
| 每股收益（稀释后） | $0.32 | $0.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRLC
| Q1 26 | — | $252.3M | ||
| Q4 25 | $168.4M | $266.5M | ||
| Q3 25 | $87.3M | $266.2M | ||
| Q2 25 | $82.4M | $248.4M | ||
| Q1 25 | $65.0M | $217.7M | ||
| Q4 24 | $69.1M | $217.2M | ||
| Q3 24 | $51.6M | $201.9M | ||
| Q2 24 | $73.8M | $187.2M |
净利润ESPRLC
| Q1 26 | — | $51.6M | ||
| Q4 25 | — | — | ||
| Q3 25 | $-31.3M | $44.3M | ||
| Q2 25 | $-12.7M | $38.2M | ||
| Q1 25 | $-40.5M | $11.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | $14.5M | ||
| Q2 24 | $-61.9M | $14.9M |
营业利润率ESPRLC
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | 18.8% | ||
| Q3 25 | -11.4% | 21.5% | ||
| Q2 25 | 8.6% | 21.7% | ||
| Q1 25 | -34.0% | 7.2% | ||
| Q4 24 | -6.4% | 5.1% | ||
| Q3 24 | -31.0% | 8.9% | ||
| Q2 24 | 3.5% | 10.4% |
净利率ESPRLC
| Q1 26 | — | 20.5% | ||
| Q4 25 | — | — | ||
| Q3 25 | -35.9% | 16.6% | ||
| Q2 25 | -15.4% | 15.4% | ||
| Q1 25 | -62.2% | 5.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | 7.2% | ||
| Q2 24 | -83.9% | 8.0% |
每股收益（稀释后）ESPRLC
| Q1 26 | — | $0.44 | ||
| Q4 25 | $0.32 | $0.36 | ||
| Q3 25 | $-0.16 | $0.37 | ||
| Q2 25 | $-0.06 | $0.33 | ||
| Q1 25 | $-0.21 | $0.10 | ||
| Q4 24 | $-0.14 | $0.08 | ||
| Q3 24 | $-0.15 | $0.13 | ||
| Q2 24 | $-0.33 | $0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $1.5B |
| 总资产 | $465.9M | $11.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRLC
| Q1 26 | — | — | ||
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | — |
总债务ESPRLC
| Q1 26 | — | — | ||
| Q4 25 | — | $0 | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $0 | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益ESPRLC
| Q1 26 | — | $1.5B | ||
| Q4 25 | $-302.0M | $1.5B | ||
| Q3 25 | $-451.4M | $1.5B | ||
| Q2 25 | $-433.5M | $1.4B | ||
| Q1 25 | $-426.2M | $1.4B | ||
| Q4 24 | $-388.7M | $1.3B | ||
| Q3 24 | $-370.2M | $1.3B | ||
| Q2 24 | $-344.2M | $1.3B |
总资产ESPRLC
| Q1 26 | — | $11.9B | ||
| Q4 25 | $465.9M | $11.6B | ||
| Q3 25 | $364.0M | $11.1B | ||
| Q2 25 | $347.1M | $10.8B | ||
| Q1 25 | $324.0M | $10.5B | ||
| Q4 24 | $343.8M | $10.6B | ||
| Q3 24 | $314.1M | $11.0B | ||
| Q2 24 | $352.3M | $9.6B |
负债/权益比ESPRLC
| Q1 26 | — | — | ||
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ESPRLC
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $-2.7B | ||
| Q3 25 | $-4.3M | $-770.8M | ||
| Q2 25 | $-31.4M | $-713.1M | ||
| Q1 25 | $-22.6M | $-339.3M | ||
| Q4 24 | $-35.0M | $-2.6B | ||
| Q3 24 | $-35.3M | $-669.8M | ||
| Q2 24 | $-7.2M | $-932.5M |
自由现金流ESPRLC
| Q1 26 | — | — | ||
| Q4 25 | — | $-2.9B | ||
| Q3 25 | — | $-791.8M | ||
| Q2 25 | — | $-803.8M | ||
| Q1 25 | — | $-352.3M | ||
| Q4 24 | — | $-2.7B | ||
| Q3 24 | $-35.5M | $-682.3M | ||
| Q2 24 | $-7.3M | $-945.3M |
自由现金流率ESPRLC
| Q1 26 | — | — | ||
| Q4 25 | — | -1076.0% | ||
| Q3 25 | — | -297.4% | ||
| Q2 25 | — | -323.5% | ||
| Q1 25 | — | -161.8% | ||
| Q4 24 | — | -1237.8% | ||
| Q3 24 | -68.7% | -338.0% | ||
| Q2 24 | -9.9% | -504.9% |
资本支出强度ESPRLC
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 52.7% | ||
| Q3 25 | 0.0% | 7.9% | ||
| Q2 25 | 0.0% | 36.5% | ||
| Q1 25 | 0.0% | 6.0% | ||
| Q4 24 | 0.0% | 25.0% | ||
| Q3 24 | 0.3% | 6.2% | ||
| Q2 24 | 0.1% | 6.9% |
现金转化率ESPRLC
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | -17.41× | ||
| Q2 25 | — | -18.68× | ||
| Q1 25 | — | -29.07× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -46.33× | ||
| Q2 24 | — | -62.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
LC
暂无分部数据
